Cutaneous T-Cell Lymphoma: Relapsed/Refractory

The term “relapsed” refers to disease that reappears or grows again after a period of remission.

The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.

Treatment options commonly used for relapsed/refractory CTCL include:

• Brentuximab vedotin (Adcetris)
• Gemcitabine (Gemzar)
• Mogamulizumab-kpkc (Poteligeo)
• Pralatexate (Folotyn)
• Romidepsin (Istodax)
• Vorinostat (Zolinza)

To learn more about relapsed/refractory CTCL, download the Cutaneous T-Cell Lymphoma Fact Sheet.

See also:

• Clinical Trials Fact Sheet